BRPI0408026A - Quinazolinas úteis como moduladores de canais de ìon - Google Patents

Quinazolinas úteis como moduladores de canais de ìon

Info

Publication number
BRPI0408026A
BRPI0408026A BR0408026-2A BRPI0408026A BRPI0408026A BR PI0408026 A BRPI0408026 A BR PI0408026A BR PI0408026 A BRPI0408026 A BR PI0408026A BR PI0408026 A BRPI0408026 A BR PI0408026A
Authority
BR
Brazil
Prior art keywords
ion channel
channel modulators
useful
quinazolines
quinazolines useful
Prior art date
Application number
BR0408026-2A
Other languages
English (en)
Inventor
Jesus E Gonzales Iii
Dean Mitchell Wilson
Andreas Peter Termin
Peter Diederik Jan Grootenhuis
Yulian Zhang
Benjamin John Petzoldt
Lev Tyler Dewey Fanning
Timothy Donald Neubert
Roger D Tung
Esther Martinborough
Nicole Zimmermann
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BRPI0408026A publication Critical patent/BRPI0408026A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"QUINAZOLINAS úTEIS COMO MODULADORES DE CANAIS DE ìON". A presente invenção refere-se aos compostos úteis como inibidores de canais de sódio e canais de sódio com voltagem de porta. A invenção também fornece composições farmaceuticamente aceitáveis, compreendendo os compostos da invenção e métodos de uso das composições para o tratamento de vários distúrbios.
BR0408026-2A 2003-03-03 2004-03-03 Quinazolinas úteis como moduladores de canais de ìon BRPI0408026A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45145803P 2003-03-03 2003-03-03
US46379703P 2003-04-18 2003-04-18
PCT/US2004/006451 WO2004078733A1 (en) 2003-03-03 2004-03-03 Quinazolines useful as modulators of ion channels

Publications (1)

Publication Number Publication Date
BRPI0408026A true BRPI0408026A (pt) 2006-02-07

Family

ID=32965550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0408026-2A BRPI0408026A (pt) 2003-03-03 2004-03-03 Quinazolinas úteis como moduladores de canais de ìon

Country Status (20)

Country Link
US (2) US7678802B2 (pt)
EP (1) EP1608632B1 (pt)
JP (1) JP5247027B2 (pt)
KR (1) KR20050108379A (pt)
AR (1) AR044502A1 (pt)
AT (1) ATE453629T1 (pt)
AU (1) AU2004217891B2 (pt)
BR (1) BRPI0408026A (pt)
CA (1) CA2517844A1 (pt)
CL (1) CL2004000409A1 (pt)
DE (1) DE602004024873D1 (pt)
ES (1) ES2338553T3 (pt)
IL (1) IL170636A (pt)
NO (1) NO20054546L (pt)
NZ (1) NZ542664A (pt)
PE (1) PE20041059A1 (pt)
RU (1) RU2378260C2 (pt)
TW (1) TW200426147A (pt)
UY (1) UY28215A1 (pt)
WO (1) WO2004078733A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713983B2 (en) * 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
AU2004289303A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
KR20070057914A (ko) * 2004-09-02 2007-06-07 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서 유용한 퀴나졸린
ATE549314T1 (de) * 2004-12-17 2012-03-15 Vertex Pharma Verfahren zur herstellung von 4-aminochinazolinen
WO2006097441A1 (en) * 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
EP1891039A1 (en) * 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
FR2891829A1 (fr) * 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
ES2377988T3 (es) 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje
WO2007059608A1 (en) * 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
KR20080089416A (ko) * 2005-12-21 2008-10-06 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP2009534458A (ja) 2006-04-26 2009-09-24 キャンサー・リサーチ・テクノロジー・リミテッド アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用
WO2007146284A2 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
WO2008023357A1 (en) * 2006-08-22 2008-02-28 Technion Research And Development Foundation Ltd. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
JP2010505794A (ja) * 2006-10-03 2010-02-25 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用なインダゾリル誘導体
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008069976A2 (en) * 2006-12-01 2008-06-12 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
MX2009010127A (es) * 2007-03-22 2009-11-05 Vertex Pharma Compuestos utiles como inhibidores de janus cinasas.
ES2637999T3 (es) * 2007-05-17 2017-10-18 Helperby Therapeutics Limited Uso de compuestos de 4-(pirrolidin-1-il)quinolina para eliminar microorganismos clínicamente latentes
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
US8324226B2 (en) * 2007-10-24 2012-12-04 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
KR101337163B1 (ko) 2008-11-14 2013-12-05 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서 퀴나졸린 유도체
WO2010135568A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
BRPI1010974A2 (pt) * 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
WO2010151595A1 (en) * 2009-06-26 2010-12-29 Schering Corporation Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers
US20110053916A1 (en) * 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
EA021113B1 (ru) * 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103360382B (zh) * 2012-03-26 2016-04-27 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
EP2865671B1 (en) * 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3109285A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103755649A (zh) * 2013-12-31 2014-04-30 李增 一种喹唑啉衍生物及其作为血管生成抑制剂的应用
CA2936886A1 (en) * 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
CN106458933B (zh) 2014-04-23 2021-03-05 泰克年研究发展基金会公司 基于喹唑啉支架的化合物、其药物组合物及使用方法
US10626094B2 (en) * 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
EP3226868A4 (en) * 2014-12-05 2018-08-15 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CA2974078A1 (en) * 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US11221329B2 (en) * 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
WO2019027765A1 (en) 2017-08-02 2019-02-07 Northwestern University SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
US11376200B2 (en) 2018-02-02 2022-07-05 Agilent Technologies, Inc. Methods and kits for using blocked 2-AA for glycan analysis
KR20210039368A (ko) 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
BR112021012950A2 (pt) * 2019-01-03 2021-09-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb
WO2021114313A1 (en) * 2019-12-14 2021-06-17 Shanghai East Hospital Ion channel antagonists/blockers and uses thereof
CA3180317A1 (en) 2020-04-17 2021-10-21 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2024258849A2 (en) * 2023-06-13 2024-12-19 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE119051C (pt)
NL292083A (pt) * 1962-09-18
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US3637693A (en) * 1968-07-12 1972-01-25 Du Pont Hydroxyarylquinazolines and their use as uv-absorbers
US3705898A (en) * 1970-01-26 1972-12-12 Morton Norwich Products Inc Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH612432A5 (pt) * 1975-05-12 1979-07-31 Sandoz Ag
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
US4377582A (en) * 1979-12-19 1983-03-22 A. H. Robins Company, Inc. 2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
JPS56120768A (en) * 1980-01-31 1981-09-22 Ciba Geigy Ag Color developing quinazoline compound
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
WO1995000524A1 (fr) * 1993-06-17 1995-01-05 Otsuka Pharmaceutical Factory, Inc. Derive de diester phosphonique
JP3722858B2 (ja) * 1993-11-25 2005-11-30 ビーエーエスエフ アクチェンゲゼルシャフト ポリアクリレート溶融体から残留揮発分を除去する方法
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
FR2751656B1 (fr) * 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
AU5597098A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP3018185B1 (ja) * 1999-02-12 2000-03-13 工業技術院長 キナゾリン誘導体又はその塩の製造方法
JP2001068452A (ja) * 1999-08-26 2001-03-16 Matsushita Electric Ind Co Ltd 回路パターン形成済シリコン基板のエッチング装置およびエッチング方法
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
JP4101053B2 (ja) 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
JP2004509876A (ja) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
WO2004030672A1 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
TWI289217B (en) * 2004-07-16 2007-11-01 Hon Hai Prec Ind Co Ltd Light guide plate
US8283354B2 (en) * 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) * 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ATE549314T1 (de) * 2004-12-17 2012-03-15 Vertex Pharma Verfahren zur herstellung von 4-aminochinazolinen
ES2377988T3 (es) 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje

Also Published As

Publication number Publication date
AU2004217891A1 (en) 2004-09-16
DE602004024873D1 (de) 2010-02-11
ATE453629T1 (de) 2010-01-15
CL2004000409A1 (es) 2005-01-07
WO2004078733A1 (en) 2004-09-16
AR044502A1 (es) 2005-09-14
US20040248890A1 (en) 2004-12-09
RU2005130486A (ru) 2006-05-10
US8343980B2 (en) 2013-01-01
ES2338553T3 (es) 2010-05-10
HK1088314A1 (en) 2006-11-03
NO20054546D0 (no) 2005-10-03
EP1608632B1 (en) 2009-12-30
TW200426147A (en) 2004-12-01
UY28215A1 (es) 2004-09-30
US7678802B2 (en) 2010-03-16
JP2006522119A (ja) 2006-09-28
PE20041059A1 (es) 2005-02-07
RU2378260C2 (ru) 2010-01-10
CA2517844A1 (en) 2004-09-16
KR20050108379A (ko) 2005-11-16
NO20054546L (no) 2005-11-25
NZ542664A (en) 2009-03-31
IL170636A (en) 2012-08-30
EP1608632A1 (en) 2005-12-28
AU2004217891B2 (en) 2011-06-23
US20110021495A1 (en) 2011-01-27
JP5247027B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
ZA200803704B (en) Biphenyl derivatives as modulators of voltage gated ion channels
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BRPI0508532A (pt) moduladores do canal de ìon
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508556A (pt) moduladores de canal iÈnico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 239/94, 403/04, 413/12; A61K 31/517; C07D 401/12, 401/04, 403/12, 401/14, 405/12, 403/14, 417/12, 409/14, 417/14, 409/12, 471/04; A61P 25/00

Ipc: C07D 239/94 (2011.01), C07D 403/04 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.